(GUTS) Fractyl Health, Inc. Business Model Canvas Research

Payers are a gatekeeper for Fractyl Health, Inc.: coverage for an outpatient metabolic procedure can decide whether clinicians adopt it at scale. In 2025, Medicare Part B covered about 67 million people, so payer evidence needs and reimbursement rules can directly shape procedure volume.

• Coverage drives adoption
• Evidence demands can delay access
• Reimbursement sets clinic volume

Fractyl Health, Inc. uses academic and metabolic-disease partners to run mechanistic work on duodenal dysfunction and pancreatic islet biology, helping test why its platform could support durable T2D and obesity remission. These ties also add outside clinical validation, which matters because obesity affects about 1 billion people worldwide and type 2 diabetes about 537 million adults.

• Supports mechanistic biology studies
• Validates remission claims externally
• Builds trust with clinicians and investors

Fractyl Health, Inc. uses medical evidence generation to build proof on glycemic control, weight loss, and durability across its platform. That data helps physicians, payers, and investors judge real-world value, and it sets the platform apart from drug-only care.

• Tracks 3 key outcomes
• Supports 3 stakeholder groups
• Shows durability beyond drugs

Fractyl Health must defend device and gene-therapy IP across Revita and Rejuva, because the company is running 2 linked programs in one metabolic disease platform. Quality systems also matter at every step: outpatient procedures need tight device controls, and biologics work needs GMP-style oversight for safety and consistency.

• Protect device and gene-therapy IP

• Run quality systems for procedures and biologics

• Manage Revita and Rejuva as one platform

That platform view helps Fractyl keep 1 strategy, 2 technologies, and 1 quality standard aligned as it moves from clinic use to regulated biologics development.

Fractyl Health, Inc.'s key resource is clinical and regulatory data from its Revita obesity and diabetes programs. Trial readouts on safety, durability, and metabolic outcomes drive valuation, de-risk reimbursement, and support partner talks; for example, the company is advancing its REMAIN-1 pivotal study, a 1-study proof point for future adoption.

• Trial data lowers clinical risk
• Durability supports payer coverage
• Regulatory filings strengthen partnerships

Fractyl Health, Inc. is headquartered in Lexington, Massachusetts, and its workforce spans R&D, clinical, regulatory, and commercial roles. That human capital is central to a dual-platform model built around medical-device and gene-therapy execution, where specialized talent drives product development, trial work, and market launch readiness.

• Lexington, Massachusetts headquarters
• R&D, clinical, regulatory, commercial teams
• Human capital is a core asset
• Supports dual-platform execution

Fractyl Health combines 2 platforms: Revita, a device-based therapy, and Rejuva, a gene-therapy platform. That gives the company multiple shots on goal in metabolic disease and more long-term strategic options if one path is slower or higher risk.

• 2 platforms, 1 company
• Device plus gene therapy
• More paths to value creation

Fractyl Health, Inc. targets type 2 diabetes and obesity, two chronic diseases that affect hundreds of millions of people worldwide. The CDC says 38.4 million U.S. people had diabetes in 2021, and WHO says more than 890 million adults had obesity in 2022, showing a large unmet need and long treatment burden.

• High-prevalence markets
• Long-term care burden
• Large unmet need

Fractyl Health, Inc. must win payer trust with evidence packs showing clinical benefit and lower total cost, because U.S. health spend reached $4.9 trillion in 2023 and insurers now price therapies on outcomes, not promotion. That makes reimbursement talks a data-first relationship, built on trials, durability, and budget impact.

• Lead with outcomes data.
• Show cost offsets clearly.
• Use payer-ready evidence packs.

Fractyl Health, Inc. works with endocrinologists, obesity clinicians, and GI specialists to drive referrals and speed protocol adoption. This specialist-to-specialist model matters in a market where obesity affects about 42% of U.S. adults and diabetes about 11.6%, so aligned care teams can also help shape future clinical guidelines.

• Drives referral flow
• Speeds protocol adoption
• Supports guideline influence

Medical conferences and peer-reviewed publications are Fractyl Health, Inc.’s key proof points: they turn clinical data into credible signals for clinicians, payers, and partners. For a science-led company, this channel can move adoption faster than sales alone because it shows the data in public, technical settings.

• Shows clinical results clearly
• Builds trust with payers
• Supports clinician adoption

Digital medical education can efficiently reach the 38.4 million U.S. adults living with diabetes, while helping providers and patients move through pre-screening, onboarding, and follow-up. For Fractyl Health, Inc., this matters most for complex treatments that need strict patient-selection criteria, because digital tools can standardize education and reduce avoidable drop-off.

• Reach providers and patients at scale
• Support pre-screening and follow-up
• Improve selection for complex care

GI and bariatric procedure centers are the natural home for Fractyl Health’s Revita because it is an outpatient therapy that fits scheduled endoscopy and weight-care workflows. In the U.S., bariatric surgery volume has stayed above 200,000 cases a year, so these centers already manage high patient flow, device handling, and follow-up visits that Revita needs.

• Outpatient setting matches Revita’s use case.
• Centers already run device-based procedures.
• Follow-up care fits existing bariatric pathways.

Coverage rules and care pathways decide who can access Fractyl Health, Inc.'s treatment, so payers and integrated care systems are key gatekeepers, not just buyers. Integrated systems focus on outcomes, use, and total cost of care; with Medicare covering about 66 million people, these decision-makers can shape adoption across large patient pools.

• Gatekeepers to treatment access
• Judge outcomes, use, and cost
• Influence coverage even without direct use

Fractyl Health, Inc. bears high regulatory and compliance costs because it must fund filings, audits, and quality systems for both gene therapy and medical devices. These costs rise as commercialization expands, since each new site, indication, or product line adds FDA, QMS, and post-market controls.

In practice, that means more spend on documentation, inspections, training, and ongoing reporting, before scale benefits appear.

• Support filings and audits
• Maintain quality systems
• Cover gene therapy rules
• Cover device compliance too
• Costs climb with scale-up

Fractyl Health, Inc. must fund sales, marketing, training, and corporate overhead before launch, and it also carries IP, legal, and admin costs; in biopharma, SG&A usually rises as products get closer to market. The key pressure point is launch readiness, where every added commercial hire and compliance step pushes burn higher.

• Launch readiness drives SG&A growth.

• IP, legal, and admin costs add fixed spend.

• Biopharma SG&A often scales pre-launch.

Fractyl Health, Inc. can earn milestone payments in development partnerships when technical or regulatory targets are hit, such as trial starts, data readouts, or FDA steps. These payments are event-linked, so they can add non-dilutive cash to fund later-stage work without waiting for product sales.

• Paid when preset milestones are reached
• Covers technical and regulatory events
• Supports later-stage development cash flow

Grants and research funding can support Fractyl Health, Inc.’s early science and translational work before product revenue scales. This non-dilutive capital is common in life sciences, so it helps fund R&D without adding equity dilution or near-term sales pressure.

• Funds early-stage research
• Reduces dilution risk
• Bridges to product revenue